Translational Approach to Predicting the Efficacy of Maraviroc-Based Regimens as HIV Preexposure Prophylaxis-Reference-Cited by-同舟云学术

Translational Approach to Predicting the Efficacy of Maraviroc-Based Regimens as HIV Preexposure Prophylaxis

Published:2020-01-27 Issue:2 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Srinivas Nithya¹,Cottrell Mackenzie¹,Maffuid Kaitlyn¹,Prince Heather A.²,Nelson Julie A. E.³,White Nicole¹,Sykes Craig¹,Dellon Evan S.²,Madanick Ryan D.²,Shaheen Nicholas J.²,Gonzalez Daniel¹,Kashuba Angela D. M.¹²

Affiliation:

1. Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA

2. Division of Gastroenterology and Hepatology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA

3. Virology, Immunology and Microbiology Core, UNC Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA

Abstract

Maraviroc-based regimens have been explored as preexposure prophylaxis (PrEP) against human immunodeficiency virus (HIV). In this study, we utilized mucosal tissue drug exposure data, combined with target concentrations generated in vitro , in a pharmacokinetic-pharmacodynamic analysis to predict the effects of drug combinations and adherence on PrEP efficacy. Mucosal tissue concentrations of maraviroc were measured in 24 healthy women.

Funder

HHS | NIH | National Institute of Allergy and Infectious Diseases

HHS | NIH | National Institute of General Medical Sciences

UNC | UNC-CH | Center for AIDS Research, University of North Carolina at Chapel Hill

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01729-19

Reference33 articles.

1. Gilead Sciences Inc. 2012. Truvada full prescribing information. Gilead Sciences Inc, Foster City, CA.

2. Changes in Kidney Function Associated With Daily Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Preexposure Prophylaxis Use in the United States Demonstration Project

3. Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis

4. A long-acting formulation of the integrase inhibitor raltegravir protects humanized BLT mice from repeated high-dose vaginal HIV challenges

5. Maraviroc and reverse transcriptase inhibitors combinations as potential preexposure prophylaxis candidates

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetics, the Immunological Impact, and the Effect on HIV Ex-Vivo Infectivity of Maraviroc, Raltegravir, and Lopinavir in Men Who Have Sex with Men Using Postexposure Prophylaxis;AIDS Research and Human Retroviruses;2023-02-15

2. The ex vivo pharmacology of HIV-1 antiretrovirals differs between macaques and humans;iScience;2022-06

3. Update and latest advances in antiretroviral therapy;Trends in Pharmacological Sciences;2022-01

4. A Randomized, Open-Label, Crossover Phase 1 Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel (the CHARM-03 Study);AIDS Research and Human Retroviruses;2021-09-14

5. An Update on Antiretroviral Therapy;Antiviral Drug Discovery and Development;2021